Jarushka Naidoo

22.9k total citations · 5 hit papers
176 papers, 7.2k citations indexed

About

Jarushka Naidoo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Jarushka Naidoo has authored 176 papers receiving a total of 7.2k indexed citations (citations by other indexed papers that have themselves been cited), including 150 papers in Oncology, 86 papers in Pulmonary and Respiratory Medicine and 24 papers in Immunology. Recurrent topics in Jarushka Naidoo's work include Cancer Immunotherapy and Biomarkers (123 papers), Lung Cancer Treatments and Mutations (65 papers) and Colorectal Cancer Treatments and Studies (46 papers). Jarushka Naidoo is often cited by papers focused on Cancer Immunotherapy and Biomarkers (123 papers), Lung Cancer Treatments and Mutations (65 papers) and Colorectal Cancer Treatments and Studies (46 papers). Jarushka Naidoo collaborates with scholars based in United States, Ireland and Italy. Jarushka Naidoo's co-authors include Jedd D. Wolchok, David B. Page, Katja Schindler, Bob T. Li, Mario E. Lacouture, Michael A. Postow, Louise C. Connell, Julie R. Brahmer, Evan J. Lipson and Patrick M. Forde and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Jarushka Naidoo

167 papers receiving 7.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

2015 1.2k citations Jarushka Naidoo et al. profile →
Cardiovascular toxicities associated with immune checkpoint inhibitors

2019 342 citations Evan J. Lipson, Jarushka Naidoo et al. profile →
Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets

2016 325 citations Natasha Rekhtman, M. Catherine Pietanza et al. Clinical Cancer Research profile →
Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer

2020 320 citations Jiajia Zhang, Patrick M. Forde et al. profile →
Immune-related adverse events and the balancing act of immunotherapy

2022 219 citations Jarushka Naidoo et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jarushka Naidoo United States	39	5.7k	2.6k	1.4k	981	853	176	7.2k
Evan J. Lipson United States	41	5.9k 1.0×	1.6k 0.6×	2.2k 1.6×	1.4k 1.4×	524 0.6×	126	7.7k
Stéphane Champiat France	32	5.4k 1.0×	1.9k 0.7×	1.9k 1.4×	883 0.9×	510 0.6×	130	7.2k
Aaron S. Mansfield United States	40	3.8k 0.7×	2.4k 0.9×	1.0k 0.7×	1.2k 1.2×	1.0k 1.2×	254	6.2k
Jean‐Pierre Delord France	43	5.5k 1.0×	2.0k 0.8×	1.7k 1.2×	2.2k 2.3×	789 0.9×	260	8.4k
Stephen V. Liu United States	42	4.2k 0.7×	2.5k 1.0×	619 0.4×	1.7k 1.8×	1.1k 1.3×	341	6.9k
Marie Wislez France	47	4.5k 0.8×	4.1k 1.6×	1.3k 0.9×	2.0k 2.0×	979 1.1×	284	8.1k
Koichi Azuma Japan	42	3.3k 0.6×	3.0k 1.2×	826 0.6×	1.5k 1.5×	850 1.0×	266	6.2k
Ahmad A. Tarhini United States	46	5.6k 1.0×	1.2k 0.5×	3.6k 2.5×	2.4k 2.5×	508 0.6×	276	8.0k
Lars Bastholt Denmark	42	4.2k 0.7×	1.7k 0.7×	1.1k 0.8×	1.8k 1.8×	984 1.2×	183	8.3k
Jean‐Marie Michot France	37	3.6k 0.6×	937 0.4×	1.2k 0.9×	1.1k 1.1×	468 0.5×	199	5.7k

Countries citing papers authored by Jarushka Naidoo

Since Specialization

Citations

This map shows the geographic impact of Jarushka Naidoo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jarushka Naidoo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jarushka Naidoo more than expected).

Fields of papers citing papers by Jarushka Naidoo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jarushka Naidoo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jarushka Naidoo. The network helps show where Jarushka Naidoo may publish in the future.

Co-authorship network of co-authors of Jarushka Naidoo

This figure shows the co-authorship network connecting the top 25 collaborators of Jarushka Naidoo. A scholar is included among the top collaborators of Jarushka Naidoo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jarushka Naidoo. Jarushka Naidoo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Roy, Gargi, Bryan T. Hennessy, Oscar S. Breathnach, et al.. (2025). Cutaneous Immune‐Related Adverse Events and Efficacy of Immune Checkpoint Inhibitors for Patients With Advanced Solid Organ Malignancies. International Journal of Dermatology. 65(4). 790–796.

Freitas, Declan de, et al.. (2025). Cytokine release syndrome in solid tumors. Cancer. 131(17). e70069–e70069. 2 indexed citations

Durm, Greg Andrew, Hirva Mamdani, Sandra K. Althouse, et al.. (2025). Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell lung cancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081. Journal for ImmunoTherapy of Cancer. 13(7). e010316–e010316. 1 indexed citations

Mountzios, Giannis, Jarushka Naidoo, Chao Wang, et al.. (2024). Beyond Chemoimmunotherapy in Advanced Non–Small Cell Lung Cancer: New Frontiers, New Challenges. American Society of Clinical Oncology Educational Book. 44(3). 14 indexed citations

Naidoo, Jarushka, et al.. (2024). Is Immunotherapy Beneficial in Patients with Oncogene-Addicted Non-Small Cell Lung Cancers? A Narrative Review. Cancers. 16(3). 527–527. 4 indexed citations

Patel, Sandip Pravin, Teresa Alonso‐Gordoa, Susana Banerjee, et al.. (2024). Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 12(2). e007340–e007340. 25 indexed citations

Lavaud, Pernelle, Lodovica Zullo, Jarushka Naidoo, et al.. (2024). Early-Stage Non-Small Cell Lung Cancer: New Challenges with Immune Checkpoint Blockers and Targeted Therapies. Cancers. 16(16). 2779–2779. 9 indexed citations

O’Reilly, David, Min Yuen Teo, Grainne M. O’Kane, et al.. (2024). Toxicity of immune checkpoint inhibitors and tyrosine kinase inhibitor combinations in solid tumours: a systematic review and meta-analysis. Frontiers in Oncology. 14. 1380453–1380453. 5 indexed citations

Naidoo, Jarushka, Catherine J. Murphy, Michael B. Atkins, et al.. (2023). Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology. Journal for ImmunoTherapy of Cancer. 11(3). e006398–e006398. 73 indexed citations

10.

Zubiri, Leyre, Vartan Pahalyants, Nicholas Theodosakis, et al.. (2022). Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study. Journal for ImmunoTherapy of Cancer. 10(6). e004670–e004670. 53 indexed citations

11.

Shaikh, Fyza Y., James R. White, Joell J. Gills, et al.. (2021). A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors. Clinical Cancer Research. 27(9). 2571–2583. 27 indexed citations

12.

Naidoo, Jarushka, et al.. (2021). Immunotherapy for Stage III NSCLC: Durvalumab and Beyond. SHILAP Revista de lepidopterología. 8 indexed citations

13.

Chen, Xuguang, Khadija Sheikh, Erica C. Nakajima, et al.. (2021). Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies. The Oncologist. 26(10). e1822–e1832. 39 indexed citations

14.

Johnson, Douglas B., Kerry L. Reynolds, Ryan J. Sullivan, et al.. (2020). Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research. The Lancet Oncology. 21(8). e398–e404. 78 indexed citations

15.

Sears, Catherine R., Tobias Peikert, Jennifer D. Possick, et al.. (2019). Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor–related Pneumonitis. An Official American Thoracic Society Research Statement. American Journal of Respiratory and Critical Care Medicine. 200(6). e31–e43. 96 indexed citations

16.

Danilova, Ludmila, Valsamo Anagnostou, Justina X. Caushi, et al.. (2018). The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity. Cancer Immunology Research. 6(8). 888–899. 99 indexed citations

17.

Moseley, Kendall F., Jarushka Naidoo, Clifton O. Bingham, et al.. (2018). Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series. Journal for ImmunoTherapy of Cancer. 6(1). 104–104. 78 indexed citations

18.

Rekhtman, Natasha, M. Catherine Pietanza, Matthew D. Hellmann, et al.. (2016). Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets. Clinical Cancer Research. 22(14). 3618–3629. 325 indexed citations breakdown →

19.

Naidoo, Jarushka & Alexander Drilon. (2014). Molecular Diagnostic Testing in Non-Small Cell Lung Cancer. 10(4). 11 indexed citations

20.

Naidoo, Jarushka, et al.. (2013). Prophylactic cranial irradiation in small cell lung cancer: a single institution experience. Irish Journal of Medical Science (1971 -). 183(1). 129–132. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact